Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

Who is this study for? Patients with osteoporosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 120
Healthy Volunteers: No
View:

• Osteoporotic patients who want to take teriparatide and denosumab

Locations
Other Locations
Japan
Yukio Nakamura
Recruiting
Matsumoto
Time Frame
Start Date: October 9, 2018
Estimated Completion Date: October 8, 2025
Participants
Target number of participants: 90
Treatments
Active Comparator: TPTD 6M
Active Comparator: TPTD 6-12M
Active Comparator: TPTD 12-24M
Related Therapeutic Areas
Sponsors
Leads: Shinshu University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials